Cancer leading cause of death among people with diabetes

 

London, UK (February 4, 2021) — This is the finding of an 18-year-study of over 300,000 people with diabetes in England, from scientists from Imperial College London and published in the journal The Lancet Diabetes & Endocrinology.

Thursday Feb 4th is World Cancer Day.

The research, funded by the Wellcome Trust, reveals that between 2001-2018 heart disease and stroke were no longer the leading causes of death among people with diabetes, as they were 18 years ago.

Diabetes affects 4.7 million people in the UK, and is caused by the body being unable to regulate blood sugar levels. Around 90 per cent have type 2 diabetes, which is associated with lifestyle factors such as high blood pressure and excess weight.

The remainder have type 1 diabetes, which is caused by the body attacking the cells that produce insulin, the hormone that controls blood sugar.

In the study, researchers from Imperial’s School of Public Health looked at anonymised primary care data from 313,907 people in England with diabetes between 2001-2018, and linked this with death data from the Office of National Statistics.

The study revealed death rates for those with diabetes declined in the study period by 32 per cent for men, and 31 per cent for women.

The team explain deaths from heart disease and stroke have reduced across the whole population, including those without diabetes.

Dr Jonathan Pearson-Stuttard, lead author of the study, said: „Improvements in risk factors such as smoking and blood pressure, along with progress in medical treatments have contributed to large falls in deaths from heart disease and stroke. The improvements have been even greater in those with diabetes. This has resulted in vascular conditions accounting for around 25 per cent of all deaths in those with diabetes compared to 45 per cent 20 years ago.

„In contrast, improvements in cancer death rates have been much more modest, with improvements in those with diabetes lagging behind the general population. It is striking that cancer is now the leading cause of death in England among people with diabetes and the leading contributor to excess death compared to those without diabetes. Added to this is the fact the UK continues to lag behind other EU countries in terms of cancer survival rates.“

The findings also showed people with diabetes were more likely to die from dementia, liver disease, or respiratory disease in 2018 than people without diabetes.

Death rates were higher in those with diabetes compared to those without in almost all causes studied. Death rates for liver disease and dementia were twice as high in those with diabetes compared to those without in 2018, while respiratory death rates were 80 per cent higher.

he research team say individuals with diabetes have up to a two-fold increased risk of dementia compared with those without diabetes. The precise link for this is unclear but there are several shared risk factors such as smoking, obesity and poor diet between diabetes and dementia.

The increase in liver disease could be due to the high levels of obesity among people with diabetes, and a higher alcohol consumption.

The team call for guidance around the treatment of diabetes to be updated, to ensure patients and clinicians are aware of the breadth of conditions they are at higher risk of including cancer, dementia and liver disease.

They add that the reasons for cancer being the leading cause of death are unclear, but could be linked to the fact people with diabetes are more likely to be overweight, and excess weight is a leading risk factor for cancer.

The team also highlight limitations of the study, such as the inability to differentiate between type one and two diabetes in the data, and the fact around 20 per cent of people with diabetes in the UK are undiagnosed.

Professor Edward Gregg, senior author of the study added: „This study is another reminder that as people die less from cardiovascular diseases, diabetes still leads to a wide range of other problems. The diversification of the big contributors to death here included cancers, dementia and respiratory diseases. This, and the current experience with COVID-19, is a reminder that we need to take an increasingly broad view about what prevention means for people with diabetes.“

 

 


Imperial College London, 04.02.2021 (tB).

Schlagwörter: ,

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…